Abstract
We describe validation of a COVID-19 antibody test for detection of anti-SARS-CoV-2 receptor-binding domain (RBD) IgG antibodies in blood plasma utilizing ethically sourced reagents not derived from aborted fetal cell lines. The test demonstrated specificity of 100% (95% confidence intervals 77.2–100%) and sensitivity of 100% (95% confidence intervals 79.6–100%) when evaluating blood specimens previously determined to be negative (n = 13) or positive for anti-SARS-CoV-2 RBD IgG antibodies due to natural SARS-CoV-2 exposure (n = 13) or COVID-19 vaccination (n = 15). The test was used to screen 230 blood specimens from individuals with unknown SARS-CoV-2 exposure (n = 103) or that were naturally exposed to SARS-CoV-2 (n = 44), received a COVID-19 vaccine (n = 66), or received a COVID-19 vaccine before or after SARS-CoV-2 exposure (n = 17). Ninety-nine percent (95% confidence intervals 95.7–100%) of the 127 blood specimens from individuals that were naturally exposed, vaccinated, or both vaccinated and naturally exposed were positive for anti-SARS-CoV-2 RBD IgG which was consistent with the high sensitivity of our test. This COVID-19 antibody test, now named the PL COVID-19 RBD IgG antibody test, represents an effective and ethical alternative to commercially available COVID-19 antibody tests that utilize reagents derived from aborted fetal lines.
Keywords
Get full access to this article
View all access options for this article.
References
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
